- Aucune donnée
Français
- English
- 简体中文
- 繁体中文
- Français
- Русский
- Italiano
- 日本語
- 한국어
- Português
- Deutsch
- Español
- Türkçe
- Ελληνικά
- Nederlands
- Tiếng Việt
- Polski
Recently, a start-up company co founded by Nobel laureate Hideyoshi Nakamura in San Francisco plans to commercialize nuclear fusion reactors using laser technology around 2030.Hideyoshi Nakamura won the 2014 Nobel Prize in Physics for inventing blue light-emitting diodes. He founded Blue Laser Fusion in Palo Alto, California in November 2022. Partners include Hiroaki Ohta, former CEO of drone manu...
Photon Automation, Inc., headquartered in Greenfield, Indiana, has been committed to providing automated laser technology solutions since 2000. The company is pleased to announce the opening of its state-of-the-art laser application laboratory in Farmington Hills, Michigan. This 7400 square foot facility will be led by renowned laser physicist Dr. Najah George, who has over 35 years of extensive e...
Recently, the Xi'an Institute of Optics and Fine Mechanics of the Chinese Academy of Sciences has made significant progress in the field of intelligent spectral environmental perception. Relevant research results have been published in the top journal in the field of environmental science, Environmental Science&Technology (Nature Index, 5-Year IF: 11.7), and have been selected as cover papers....
Recently, Weiyuan Photon (Shenzhen) Technology Co., Ltd. (hereinafter referred to as "Weiyuan Photon") announced the completion of a B+round of financing, with investors including Yicun Capital, Chenfeng Capital, and Beijing Guoqian Investment. The specific amount has not been disclosed. According to its official website, MicroSource Photonics was founded in November 2018, with the main members...
On July 3rd local time, Swiss ophthalmic care giant Alcon announced the acquisition of Israeli medical technology company Belkin Vision and its laser equipment assets for treating glaucoma.The transaction includes a prepayment of $81 million, of which approximately $65 million is in cash. In addition, if Alcon can establish this technology as the preferred first-line treatment option for clinical ...